PRECIGEN, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
PRECIGEN, INC. (PGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 43.52 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-04
- PRECIGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 43.52M shares.
- PRECIGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- PRECIGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-03-31 was 2.04M shares, a 1.25% increase year-over-year.
- PRECIGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-09-30 was 0.00 shares, a 100.00% decline year-over-year.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2026-06-30 | 43.52M shares 10-Q · filed 2026-08-04 | 43.28M shares 10-Q · filed 2026-08-04 | |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-10 | ||
| 2015-03-31 | 2.04M shares 10-Q · filed 2016-05-10 | ||
| 2014-09-30 | 0.00 shares 10-Q · filed 2014-11-13 | 0.00 shares 10-Q · filed 2014-11-13 | |
| 2014-03-31 | 2.01M shares 10-Q · filed 2015-05-11 | ||
| 2013-09-30 | 1.85M shares 10-Q · filed 2014-11-13 | 0.00 shares 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |